Nov 18, 2020 / 04:25PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Hey, everybody. Welcome to a great session here at the Jefferies virtual London healthcare conference. I am virtually here in London as evidenced by my background there. And my good friends at Moderna CEO, Stéphane Bancel; and Lavina Talukdar, who heads up IR here with me, probably, in Boston or wherever they're at. But great to have you with us. We also may be joined by CFO, David Meline, to talk about revenues as well, which is always an important topic for the audience. So when he's here, we'll bring him in.
Well, first of all, I mean, I just wanted to start off, Stéphane. Congrats on everything to date. I think everyone is hugely proud and happy with the results recently and really happy with all the execution.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystI just wanted to start off by asking from a high level to talk about the profile of your vaccine. And I don't want to get into differentiation thing, but just talk
Trustpilot
